Back to the drug test guide

LSD Test Evidence

Has Caused a False Positive

Bupropion

Source Vidal and Skripuletz, Ther Drug Monit 2007

What It Found

  • Investigators found bupropion in a patient whose LSD and amphetamine CEDIA screens failed confirmation.

Test Studied

  • CEDIA LSD in a clinical report

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

What It Found

  • A separate historical EMIT urine-spiking test implicated bupropion, as identified in Saitman Table VI.

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

2 sources Vidal and Skripuletz, Ther Drug Monit 2007 Ritter et al., Clin Chem 1997

Keep in Mind

  • One clinical report and a historical laboratory experiment cannot estimate the risk on a current kit at usual doses.

Sertraline

Source Citterio-Quentin et al., J Anal Toxicol 2012

What It Found

  • A 2012 CEDIA investigation followed a patient who had taken extra sertraline and found interference when sertraline was added to urine.

Test Studied

  • Microgenics CEDIA LSD

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

What It Found

  • A separate historical EMIT spiking experiment also implicated sertraline, as identified in Saitman Table VI.

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

All 3 sources Citterio-Quentin et al., J Anal Toxicol 2012 Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Keep in Mind

  • Dose and assay both matter.
  • The case and laboratory studies do not establish an individual probability with standard therapy.

Amitriptyline

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies amitriptyline as one of the interferents in that experiment.

Keep in Mind

  • The EMIT-specific drug identity comes from review Table VI.

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • In the CEDIA series the drug was detected among patients with unconfirmed LSD screens.

Keep in Mind

  • The CEDIA series did not isolate a cause for an individual specimen.

Test Studied

  • CEDIA DAU LSD in a separate case series

2 sources Grobosch and Lemm-Ahlers, J Anal Toxicol 2002 Ritter et al., Clin Chem 1997

Keep in Mind

  • Neither study measured the risk at a usual dose.

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Benzphetamine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies benzphetamine as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Brompheniramine

Source Wiegand et al., J Anal Toxicol 2002

What It Found

  • Wiegand and colleagues challenged three assays with 144 compounds.

Keep in Mind

  • The original abstract supplies the study design and overall comparison.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Saitman Table VI identifies brompheniramine as producing a positive EMIT II result at 25 micrograms/mL.

Keep in Mind

  • The drug-specific concentration comes from the review’s table.

Both sources Wiegand et al., J Anal Toxicol 2002 Saitman et al., J Anal Toxicol 2014

Keep in Mind

  • Clinical likelihood at a typical dose was not measured.

Test Studied

  • Dade Behring EMIT II LSD (0.5 ng/mL cutoff)

Buspirone

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies buspirone as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Cephradine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies cephradine as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Chlorpromazine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies chlorpromazine as one of the interferents in that experiment.

Keep in Mind

  • The study-specific attribution comes from review Table VI.

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

What It Found

  • The later Siemens instructions also specifically flag chlorpromazine use when interpreting a positive screen.

Keep in Mind

  • The later instructions do not estimate how often people taking chlorpromazine will have a positive screen.

Test Studied

  • Siemens Syva EMIT II LSD revision 08

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Desipramine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies desipramine as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Diltiazem

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies diltiazem as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Doxepin

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies doxepin as one of the interferents in that experiment.

Keep in Mind

  • The EMIT-specific drug identity comes from review Table VI.

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • In the CEDIA series the drug was detected among patients with unconfirmed LSD screens.

Keep in Mind

  • The CEDIA series did not isolate a cause for an individual specimen.

Test Studied

  • CEDIA DAU LSD in a separate case series

2 sources Grobosch and Lemm-Ahlers, J Anal Toxicol 2002 Ritter et al., Clin Chem 1997

Keep in Mind

  • Neither study measured the risk at a usual dose.

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Haloperidol

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies haloperidol as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Imipramine

Source Wiegand et al., J Anal Toxicol 2002

What It Found

  • Wiegand and colleagues challenged three assays with 144 compounds.

Keep in Mind

  • The original abstract supplies the study design and overall comparison.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Saitman Table VI identifies imipramine as producing a positive EMIT II result at 50 micrograms/mL.

Keep in Mind

  • The drug-specific concentration comes from the review’s table.

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

What It Found

  • The review also lists imipramine in the earlier Ritter experiment.

All 3 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014 Wiegand et al., J Anal Toxicol 2002

Keep in Mind

  • Clinical likelihood at a typical dose was not measured.

2 sources Ritter et al., Clin Chem 1997 Wiegand et al., J Anal Toxicol 2002

Test Studied

  • Historical Behring/Syva EMIT II LSD in the Ritter and Wiegand studies

Labetalol

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies labetalol as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Methylphenidate

Source Wiegand et al., J Anal Toxicol 2002

What It Found

  • Wiegand and colleagues challenged three assays with 144 compounds.

Keep in Mind

  • The original abstract supplies the study design and overall comparison.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Saitman Table VI identifies methylphenidate as producing a positive EMIT II result at 50 micrograms/mL.

Keep in Mind

  • The drug-specific concentration comes from the review’s table.

Both sources Wiegand et al., J Anal Toxicol 2002 Saitman et al., J Anal Toxicol 2014

Keep in Mind

  • Clinical likelihood at a typical dose was not measured.

Test Studied

  • Dade Behring EMIT II LSD (0.5 ng/mL cutoff)

Metoclopramide

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies metoclopramide as one of the interferents in that experiment.

Keep in Mind

  • The EMIT-specific drug identity comes from review Table VI.

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • In the CEDIA series the drug was detected among patients with unconfirmed LSD screens.

Keep in Mind

  • The CEDIA series did not isolate a cause for an individual specimen.

Test Studied

  • CEDIA DAU LSD in a separate case series

2 sources Grobosch and Lemm-Ahlers, J Anal Toxicol 2002 Ritter et al., Clin Chem 1997

Keep in Mind

  • Neither study measured the risk at a usual dose.

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Prochlorperazine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies prochlorperazine as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Risperidone

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies risperidone as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Thioridazine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies thioridazine as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Both sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Trazodone

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies trazodone as one of the interferents in that experiment.

Keep in Mind

  • Table VI supplies the historical drug identity.

2 sources Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024 Baron et al., J Anal Toxicol 2011

What It Found

  • Siemens separately measured a response near the LSD cutoff with m-CPP, a trazodone metabolite, at 33 micrograms/mL.

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

Keep in Mind

  • The contemporary experiment concerns the metabolite.

Test Studied

  • Siemens Syva EMIT II LSD revision 08

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Depends on the Brand of Test

Fentanyl

Source Gagajewski et al., Clin Chem 2002

What It Found

  • A fentanyl-associated hospital case had positive screens but no LSD or major LSD metabolite by LC-MS.

3 sources Gagajewski et al., Clin Chem 2002 Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

What It Found

  • Historical investigators reported laboratory interference at high concentrations.

Keep in Mind

  • The review attributes high-concentration spiking to the original publications.

Test Studied

  • Historical EMIT II and CEDIA LSD

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • In contrast, a CEDIA insert reported a negative response at 40 ng/mL fentanyl.

Keep in Mind

  • The negative CEDIA experiment tested a far lower concentration.

Test Studied

  • CEDIA manufacturer specificity testing

Source Oberli et al., Eur Heart J Case Rep 2018

What It Found

  • A case report attributed an unconfirmed urine LSD screen to fentanyl given in the emergency department several hours earlier.

Keep in Mind

  • The authors describe the timing and negative confirmation but give no drug-only challenge on the patient's assay.

2 sources Gagajewski et al., Clin Chem 2002 Oberli et al., Eur Heart J Case Rep 2018

Test Studied

  • Hospital urine LSD screen, reagent not identified, followed by confirmatory chromatography

Dextroamphetamine

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

What It Found

  • The manufacturer measured a response near the LSD cutoff with dextroamphetamine at 500 µg/mL in its specificity evaluation.

Test Studied

  • Siemens Syva Emit II LSD, revision 08, 0.5 ng/mL LSD cutoff

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • A separate CEDIA insert lists a negative result for amphetamine at 500,000 ng/mL without specifying the isomer.

Test Studied

  • Thermo CEDIA LSD

Both sources Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024 Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

Keep in Mind

  • This is a urine assay experiment.
  • The concentration in the experiment is not a medication dose or an estimate of the chance of a positive result.

Ergonovine

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Saitman Table VI reports an older EMIT II response at 4 micrograms/mL ergonovine.

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

What It Found

  • Siemens revision 08 reports a near-cutoff response at 1 microgram/mL.

Test Studied

  • Revised Siemens EMIT II

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • CEDIA reported 0.0% cross-reactivity at 10 micrograms/mL.

Test Studied

  • CEDIA LSD

Source Cassells et al., J Anal Toxicol 1996

What It Found

  • Another microplate assay showed very weak reactivity.

Test Studied

  • An experimental microplate assay

2 sources Wiegand et al., J Anal Toxicol 2002 Saitman et al., J Anal Toxicol 2014

Keep in Mind

  • The older study’s concentration was extracted from the review table.

Test Studied

  • Dade Behring EMIT II LSD (0.5 ng/mL cutoff)

Fluoxetine

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies fluoxetine as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • The CEDIA manufacturer reported a negative response when it tested fluoxetine at 400 micrograms/mL.

Test Studied

  • CEDIA LSD urine assay

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Lysergol

Source Wiegand et al., J Anal Toxicol 2002

What It Found

  • Wiegand and colleagues challenged three assays with 144 compounds.

Keep in Mind

  • The original abstract supplies the study design and overall comparison.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Saitman Table VI identifies lysergol as producing a positive EMIT II result at 25 micrograms/mL.

Keep in Mind

  • The drug-specific concentration comes from the review’s table.

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • The CEDIA insert reported zero measurable cross-reactivity at 5 micrograms/mL, a lower challenge concentration.

Test Studied

  • CEDIA LSD

2 sources Wiegand et al., J Anal Toxicol 2002 Saitman et al., J Anal Toxicol 2014

Keep in Mind

  • Clinical likelihood at a typical dose was not measured.

Test Studied

  • Dade Behring EMIT II LSD (0.5 ng/mL cutoff)

Methamphetamine

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

What It Found

  • The manufacturer measured a response near the LSD cutoff with methamphetamine at 100 µg/mL in its specificity evaluation.

Test Studied

  • Siemens Syva Emit II LSD, revision 08, 0.5 ng/mL LSD cutoff

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • Thermo’s CEDIA LSD test remained negative with methamphetamine at 200,000 ng/mL.
  • The insert does not specify the isomer.

Test Studied

  • Thermo CEDIA LSD

Both sources Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024 Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

Keep in Mind

  • This is a urine assay experiment.
  • The concentration in the experiment is not a medication dose or an estimate of the chance of a positive result.

Methysergide

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

What It Found

  • The manufacturer measured a response near the LSD cutoff with methysergide at 3 µg/mL in its specificity evaluation.

Test Studied

  • Siemens Syva Emit II LSD, revision 08, 0.5 ng/mL LSD cutoff

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • Thermo’s CEDIA insert reports 0.0% cross-reactivity for methysergide maleate at 50,000 ng/mL.

Test Studied

  • Thermo CEDIA LSD

Both sources Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024 Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

Keep in Mind

  • This is a urine assay experiment.
  • The concentration in the experiment is not a medication dose or an estimate of the chance of a positive result.

Phencyclidine

Source Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024

What It Found

  • The manufacturer measured a response near the LSD cutoff with phencyclidine at 30 µg/mL in its specificity evaluation.

Test Studied

  • Siemens Syva Emit II LSD, revision 08, 0.5 ng/mL LSD cutoff

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • Thermo’s CEDIA LSD test remained negative with phencyclidine at 500,000 ng/mL.

Test Studied

  • Thermo CEDIA LSD

Both sources Siemens Healthineers. Syva EMIT II LSD Assay. Instructions for use, revision 08, sections…, 2024 Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

Keep in Mind

  • This is a urine assay experiment.
  • The concentration in the experiment is not a medication dose or an estimate of the chance of a positive result.

Verapamil

Source Ritter et al., Clin Chem 1997

What It Found

  • Ritter and colleagues reproduced positive EMIT results by adding individual medicines to normal urine.

Keep in Mind

  • The original abstract describes the experiment.
  • A positive spiked specimen does not establish the likelihood at a prescribed dose.

Source Saitman et al., J Anal Toxicol 2014

What It Found

  • Table VI of the subsequent Saitman review identifies verapamil as one of the interferents in that experiment.

Keep in Mind

  • The individual drug attribution comes from the review table.

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • The CEDIA manufacturer reported a negative response when it tested verapamil at 500 micrograms/mL.

Test Studied

  • CEDIA LSD urine assay

2 sources Ritter et al., Clin Chem 1997 Saitman et al., J Anal Toxicol 2014

Test Studied

  • Behring/Syva EMIT II LSD urine assay (0.5 ng/mL cutoff, 1997 study)

Suspected, but Not Proven

Atracurium

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified atracurium among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Bupivacaine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified bupivacaine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Diphenhydramine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified diphenhydramine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Doxylamine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified doxylamine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Lidocaine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified lidocaine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Mepivacaine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified mepivacaine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Pipamperone

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified pipamperone among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Prilocaine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified prilocaine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Promethazine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified promethazine among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens

Ranitidine

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • Ranitidine was detected among patient specimens whose CEDIA LSD screens failed confirmation.

Keep in Mind

  • Finding ranitidine in a discrepant urine did not establish the cause.

Test Studied

  • REMEDI HS profiling of discrepant specimens

Source Thermo Fisher Scientific. CEDIA LSD Assay instructions for use, specificity tables…, 2019

What It Found

  • Separately, the CEDIA manufacturer reported a negative response when it tested ranitidine at 500 micrograms/mL.

Keep in Mind

  • The negative spiking result further limits the evidence for attributing an LSD screen to ranitidine.

Tramadol

Source Grobosch and Lemm-Ahlers, J Anal Toxicol 2002

What It Found

  • The investigators identified tramadol among candidate interferents after profiling patient specimens whose LSD screens did not confirm by chromatography.

Keep in Mind

  • Detection in discrepant urine is a lead.
  • The report does not demonstrate that this individual drug independently caused the result or quantify the risk at usual doses.

Tests Studied

  • CEDIA DAU LSD
  • REMEDI HS profiling of discrepant specimens